A YORK medical technology business has received a grant from the European Commission to further its research.

Tissue Regenix, based at York Science Park, received just more than €280,000 (about £248,000) grant funding from the European Commission.

The money will fund further research into the company’s dCell technology, whereby the cells are stripped out of the organ tissue of animals, so it can then be transplanted into the human body without being rejected by the patient’s body.

The tissue is then repopulated by human cells to become a living part of the body.

The grant, provided under the European Union’s research and development programme, Seventh Framework Programme (FP7), will fund the further development of applications of dCell grafts in cardiac and vascular surgery.

Antony Odell, managing director of Tissue Regenix, said: “We are pleased to have been chosen by the European Commission to receive this funding, a recognition which provides further validation for our technology platform as well as allowing us to explore additional opportunities to expand our product pipeline at minimum cost to the company.”